title: The new kid on the block: RET in lung cancer.
abstract: RET has recently been identified as a potential new oncogenic driver in a subset of patients with non-small cell lung cancer (NSCLC). In this issue of Cancer Discovery, Drilon and colleagues report preliminary trial data with a RET inhibitor in RET fusion-positive NSCLC, validating RET as a therapeutic target in lung cancer.
authors.affiliation: Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
authors.forename: Justin F
authors.initials: JF
authors.lastname: Gainor
authors.forename: Alice T
authors.initials: AT
authors.lastname: Shaw
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000077192:Adenocarcinoma of Lung; D000813:Anilides / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D051096:Proto-Oncogene Proteins c-ret / Q000096:biosynthesis*; D011725:Pyridines / Q000627:therapeutic use*
chemical_list: D000813:Anilides; D011725:Pyridines; C558660:cabozantinib; D051096:Proto-Oncogene Proteins c-ret; C099282:RET protein, human